NeOnc confirms August 12 topline readout for Phase 2a NEO100 glioma study
The company reported second-quarter 2026 results, an FDA feedback session on NEO212, and cash of $2.0 million alongside undrawn credit facilities.
NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) said on August 10, 2026 that it will present topline data from its Phase 2a study of intranasal NEO100 in patients with recurrent IDH1-mutant high-grade glioma during an investor call on August 12. The company said it finished the topline analysis of the fully enrolled Phase 2a study and will walk through the results on a call and webcast that day.1 The call is set for Wednesday, August 12, 2026, at 5:30 a.m. Pacific Time, or 8:30 a.m. Eastern Time.1
On the regulatory side, NeOnc said it received UAE IND approval in June for NEO100, covering all three NEO100 programs spanning adult Phase 1 through Phase 2 as well as pediatric studies.1 It also secured a separate UAE clearance for its other CNS candidate: the company said it obtained UAE IND approval for NEO212 in June, which will allow Phase 2 testing in the UAE of its oral drug combining perillyl alcohol and temozolomide.1 Domestically, NeOnc said it got written FDA feedback in July on NEO212's development, including manufacturing controls and a planned shift from capsule to tablet form, then met with the FDA to discuss next steps and expects official meeting minutes in August 2026.1
Financially, the company reported cash and equivalents of about $2.0 million as of June 30, 2026, plus an undrawn $10.0 million credit line from related party HCWG.1 R&D spending rose to $2.6 million from $0.7 million a year earlier,1 while net loss was $14.2 million, or $(0.58) per diluted share, versus $5.7 million, or $(0.30) per share, in the same quarter of 2025.1 About $44.5 million remained available under its Mast Hill equity facility as of quarter-end.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.